Human platelets stimulated by thrombin produce platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when April 1985) It has been shown [Touqui, Jacquemin & Vargaftig (1983) Thromb. Haemostasis 50, 163; Touqui, Jacquemin & Vargaftig (1983) Biochem. Biophys. Res. Commun. 110, 890-893; Alam, Smith & Melvin (1983) Lipids 18, 534-538; Pieroni & Hanahan (1983) Arch. Biochem. Biophys. 224, [485] [486] [487] [488] [489] [490] [491] [492] [493] that rabbit platelets inactivate exogenous PAF (platelet-activating factor, PAF-acether) by a deacetylationreacylation mechanism. The deacetylation step is catalysed by an acetyl hydrolase sensitive to the serine-hydrolase inhibitor PMSF (phenylmethanesulphonyl fluoride) [Touqui, Jacquemin, Dumarey & Vargaftig (1985) Biochim. Biophys. Acta 833, [111] [112] [113] [114] [115] [116] [117] [118] . We report here that human platelets can produce PAF on thrombin stimulation. This production is marginal and transient, reaching a maximum at 10min and decreasing thereafter. In contrast, 10-12 times more PAF is produced when platelets are treated with PMSF and stimulated with thrombin. Under these conditions, the maximum formation is observed at 30 min and no decline occurs for up to 60min after stimulation. In addition, these platelets (treated with PMSF and stimulated with thrombin) incorporate exogenous labelled acetate in the 2-position of PAF, probably by an acetyltransferase-dependent mechanism. Production of PAF by human platelets during physiological stimulation can be demonstrated when PAF degradation is suppressed by the acetyl-hydrolase inhibitor PMSF.
Platelet-activating factor (PAF; Benveniste et al., 1977; Demopoulos et al., 1979 ) is a phospholipid mediator of anaphylaxis and inflammation that induces platelet aggregation and secretion Cazenave et al., 1979) . It is formed by various cell types Vargaftig et al., 1979) , including platelets, during stimulation by agents such as thrombin, collagen and the ionophore A23187 (Chignard et al., 1980) , by a Ca2+-dependent deacylationreacetylation reaction involving a membranebound precursor, alkylacyl-GPC (l-O-alkyl-2-acylAbbreviations used: PAF, platelet-activating factor (PAF-acether, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine); alkylacyl-GPC, 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine; lyso-PAF, alkyl-lysoglycerophosphocholine; PC, phosphatidylcholine; PE, phosphatidylethanolamine; TTBSA, Tris Tyrode's buffer (Mustard et al., 1972) containing 0.25% bovine serum albumin; DMSO, dimethyl sulphoxide; CP/CPK, creatine phosphate (phosphocreatine)/creatine phosphokinase.
sn-glycero-3-phosphocholine) (Touqui et al., 1985) . The initial step in PAF biosynthesis is the activation of a phospholipase A2 Albert & Snyder, 1983; Touqui et al., 1985) , leading to the biologically inactive intermediate lyso-PAF (alkyl-lysoglycerophosphocholine). Subsequent acetylation of lyso-PAF by an acetyltransferase generates PAF. The activity of the latter enzyme appears to be the rate-limiting step in the PAF biosynthesis (Wykle et al., 1980; Chap et al., 1981; Alonso et al., 1982; Ninio et al., 1982; Albert & Snyder, 1983) .
Exogenous PAF can be converted by platelets into its precursor alkylacyl-GPC through the combined activities of an acetyl hydrolase and an acyltransferase (Touqui etal., 1983a (Touqui etal., ,b, 1985 Alam et al., 1983; Pieroni & Hanahan, 1983) . In contrast with its biosynthesis, the conversion of PAF into alkylacyl-GPC is independent of platelet activation and of extracellular Ca2+ (Touqui et al., 1985) .
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The production of PAF by human platelets stimulated with thrombin has not been demonstrated conclusively. In the one successful demonstration (Chignard et al., 1983) , only marginal amounts of PAF were detected. We hypothesized that rapid inactivation and conversion of PAF into the corresponding alkylacyl-GPC may explain the inability to demonstrate the formation of PAF by human platelets during physiological stimulation.
In the present study we show that human platelets preincubated with the acetyl-hydrolase inhibitor PMSF (Touqui et al., 1985) can produce large amounts of PAF after stimulation by thrombin. Under these conditions, the formation of PAF could be detected with thrombin concentrations as low as 0.1 unit/ml. Moreover, PAF formed by platelets stimulated in the presence of [3H] Paris, France) . The phospholipase A2 subunit of crotoxin from rattlesnake (Crotalus durissus terrificus) venom was purified in our laboratory by Dr. F. Radvanyi and Dr. C. Bon as described by Hendon & Fraenkel-Conrat (1971) . Plastic silica-gel plates for t.l.c. were from Merck. The column used for h.p.l.c. was a Lichrosorb Si 60 from Spectra-Physics, Paris, France. All solvents used were of h.p.l.c. grade from Fisons, Loughborough, Leicestershire, U.K.
Methods
Preparation and stimulation of platelets. Whole blood (9vol.) from normal adult volunteers, who took no medication for at least 10 days before venipuncture, was collected and anticoagulated with 0.13 M-trisodium citrate (1 vol.). Platelet-rich plasma was produced by centrifugation (20min at 200g) and platelets were washed by the method of Mustard et al. (1972) , giving a final platelet suspension of 5 x 108/ml in TTBSA. Portions of washed platelets (5 ml) were incubated with PMSF (2mM) or DMSO (vehicle) (0.25%) in controls for 15min. Platelets were then centrifuged (15min at 1400g) and resuspended in fresh TTBSA to remove PMSF. Thereafter, 1 ml portions were stirred and challenged with thrombin (2.5 units/ml final concn.) for the periods indicated in Fig. 1 (below) or with various concentrations of thrombin (0.1, 0.25, 0.5, 1 or 2.5 units/ml final concn.) for 30min. At the appropriate times, reactions were terminated by the addition of 3 ml of chloroform/methanol (1: 2, v/v) at 4°C.
Extraction and bioassay of PAF. Lipids were extracted by the method of Bligh & Dyer (1959) and stored at -20°C. The organic phase was removed and evaporated to dryness under 02-free N2. Lipid extracts were redissolved in 250y1 of water containing bovine serum albumin (0.25%) and kept at 4°C. PAF was detected by using washed rabbit platelets as a bioassay (Chignard et al., 1980 PMSF-treated or control platelets were washed and resuspended in nominally Ca2+-free TTBSA. Cytosolic fractions were prepared by homogenizing 1 ml (5 x 108 cells) by the method described by Barber & Jamieson (1970) . Cytosolic and particulate fractions were separated by centrifugation (60 min at 105 000g, 4°C). Either 1 ml of intact platelets, total homogenates or their equivalent cytosolic fractions were incubated with synthetic [3H]PAF at 37°C. The reactions were terminated with chloroform/methanol as described above, at the time points indicated in Table 2 , and lipid extracts were analysed as described by Touqui et al. (1985) .
Results
Control platelets stimulated with thrombin synthesized marginal amounts of PAF only. In contrast, this formation was markedly increased when platelets were pretreated with PMSF, washed and then stimulated with thrombin ( Fig.  1) . Washing platelets to remove PMSF from the medium was required to obtain platelets sensitive to thrombin, since omission of the washing procedure, i.e. stimulation in the presence of PMSF, resulted in no aggregation (results not shown). DMSO alone, at the 0.25% final concentration used as the vehicle for PMSF, had only a marginal effect on the production of PAF (Table  1) . The PMSF-treated platelets, when compared with the control (DMSO-treated) platelets, formed about 12 times more PAF within 30min stimulation with thrombin (Table 1 ). The amounts of PAF formed by the PMSF-treated thrombin-stimulated platelets remained practically unchanged for up to 60min. In contrast, PAF was only detected transiently in control thrombin-stimulated plate- Table 1 . EjIect of the pre-exposure of platelets to PMSF on PAF production Platelets treated with PMSF, with its solvent DMSO, or with saline (0.9% NaCl), were washed and resuspended in fresh TTBSA. Then 1 ml portions were challenged, while being stirred, with thrombin (2.5 units/ml final concn.) or with saline and the reactions were stopped at the indicated times by the addition of 3 ml of chloroform/methanol (1:2, v/v). The lipids were extracted and PAF production was measured as described under 'Methods'. Values are (Fig. 1) . The increased formation of PAF did not result from an intrinsic effect of PMSF, since when the latter was used in the absence of thrombin, no such synthesis was seen (Table 1) .
The identity of PAF formed by human platelets was checked by its h.p.l.c. and pharmacological properties. The fractions collected from h.p.l.c. that were active in inducing aggregation had a retention time similar to that of synthetic [3H]PAF (22min). The aggregating activity was insensitive to aspirin and CP/CPK, which inhibit respectively arachidonate-and ADP-induced aggregation . It was lost when the extracts were pre-incubated with snake-venom phospholipase A2 (results not shown).
The formation of PAF by thrombin-stimulated human platelets was dose-dependent (Fig. 2) . It was detected down to a concentration of 0.1 unit/ml thrombin applied to the PMSF-treated platelets and was maximal at 0.5 unit/ml. In contrast, control platelets required more than 1 unit of thrombin/ml to produce detectable amounts of PAF (0.45pmol/ml of platelets). When thrombin was replaced by ionophore A23187, a similar increase in the PAF production by PMSF-treated platelets was observed (results not shown).
These results suggested that the increased production of PAF results from the inhibition, by PMSF, of PAF deacetylation, leading to its accumulation. To test this possibility, intact platelets, their homogenate or the cytosolic fraction, were incubated with radioactive PAF. As shown in Table 2 , the intact platelets failed to metabolize PAF and the cytosolic fraction converted it into lyso-PAF. Finally, the platelet homogenate transformed PAF into alkylacyl-GPC. Formation of lyso-PAF or of alkylacyl-GPC by the cytosolic fraction and the homogenate respectively were inhibited when the platelets were Table 2 . Inhibition by PMSF of the PAF conversion by platelet homogenates and their cytosolic fractions A 5ml portion of platelets was incubated as detailed in the text with 2mM-PMSF or with its solvent, DMSO. After one centrifugation (15min at 1400g), platelets were homogenized as described by Barber & Jamieson (1970) . Then, [3H]PAF (104c.p.m./ml final concn.; 120Ci/mmol) was incubated with 1 ml of intact platelets, 1 ml of total homogenates or 1 ml of their cytosolic fractions (105000g, 60min supernatant). The reactions were stopped 10 or 30min later by the addition of 3 ml of chloroform/methanol (1:2, v/v) and the lipid extracts were subjected to t.l.c., with chloroform/methanol/NH3 (70:35:7, by vol.) as solvent system, and analysed as described by Touqui et al. (1985) . The values represent the percentage of each indicated component as compared to the total plate radioactivity (two separate expts. incubated with PMSF and washed before cell fractionation (Table 2) . Finally, pre-exposure of platelets to PMSF, followed by their stimulation with thrombin in the presence of radioactive acetate, resulted in a marked incorporation of the label into PAF. No significant incorporation of radioactive acetate was observed in PMSF-untreated platelets after 30min stimulation with thrombin (Fig. 3) . The incubation of the acetate-labelled PAF derived from platelets with purified phospholipase A2 showed that acetate was linked in the 2-position of PAF, since this enzyme is known to cleave phospholipids specifically in the sn-2 position.
Discussion
We (Touqui et al., 1985) and others (Pieroni & Hanahan, 1983; Alam et al., 1983) have shown that the metabolism of PAF by platelets is initiated by its deacetylation, catalysed by a specific acetyl hydrolase as shown by Blank et al. (1981a,b) in other cells, and leading to the biologically inactive intermediate lyso-PAF. This deacetylation may represent a detoxification of the highly active PAF.
In the present studies we demonstrate that human platelets, when stimulated with the physiological agonist thrombin, form PAF and that this formation is greatly increased (10-12 times) by PMSF. Indeed, in the presence of PMSF, which alone does not enhance the formation of this lipid, human platelets can synthetize PAF at a thrombin concentration as low as 0.1 unit/ml. We have shown previously that PMSF inhibits the deacetylation of PAF, an event mediated by a cytosolic acetyl hydrolase (Kramer et al., 1984) . Hence the enhanced formation of PAF, in the presence of PMSF, would appear to be due to inhibition of the enzyme involved in its degradation. Under our conditions, intact human platelets, in contrast with rabbit platelets (Touqui et al., 1983a) , were not able to convert exogenous PAF (Table 2) . This is probably due to the low rate of PAF uptake by human platelets in comparison with that by rabbit platelets (Hwang et al. 1983; Inarrea et al., 1984) .
In previously reported studies (Wykle et al., 1980; Chap et al., 1981; Alonso et al., 1982; Ninio et al., 1982; Albert & Snyder, 1983 ) the evaluation of the acetyltransferase activities and/or PAF synthesis were certainly underestimated because of the presence of an acetyl hydrolase, which inactivates PAF.
Our studies also show that human platelets incorporate radioactive acetate into PAF by a stimulus-dependent mechanism. This incorporation is markedly increased when platelets are first exposed to the acetyl-hydrolase inhibitor PMSF. These findings support the concept that an acetylation process is involved in the biosynthesis of PAF by human platelets and that acetylation may be better observed when deacetylation of PAF is blocked by PMSF.
Overall 
